NASDAQ:GWPH - GW Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$161.10 +1.14 (+0.71 %)
(As of 05/28/2018 01:24 AM ET)
Previous Close$161.10
Today's Range$158.50 - $161.8150
52-Week Range$92.65 - $161.82
Volume275,801 shs
Average Volume408,491 shs
Market Capitalization$4.47 billion
P/E Ratio-23.18
Dividend YieldN/A
Beta2.6

About GW Pharmaceuticals (NASDAQ:GWPH)

GW Pharmaceuticals logoGW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. Its lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates, which are in Phase I and II clinical development for the treatment of glioma, neonatal hypoxic-ischemic encephalopathy, adult epilepsy, and schizophrenia. Further, the company has license and development agreements with Otsuka Pharmaceutical Co. Ltd.; Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Receive GWPH News and Ratings via Email

Sign-up to receive the latest news and ratings for GWPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GWPH
CUSIPN/A
Phone44-12-2326-6800

Debt

Debt-to-Equity Ratio0.01
Current Ratio11.32
Quick Ratio11.22

Price-To-Earnings

Trailing P/E Ratio-23.18
Forward P/E Ratio-16.57
P/E GrowthN/A

Sales & Book Value

Annual Sales$11 million
Price / Sales406.70
Cash FlowN/A
Price / CashN/A
Book Value$20.21 per share
Price / Book7.97

Profitability

EPS (Most Recent Fiscal Year)($6.95)
Net Income$-166,900,000.00
Net Margins-1,516.94%
Return on Equity-53.37%
Return on Assets-46.73%

Miscellaneous

Employees583
Outstanding Shares27,770,000

GW Pharmaceuticals (NASDAQ:GWPH) Frequently Asked Questions

What is GW Pharmaceuticals' stock symbol?

GW Pharmaceuticals trades on the NASDAQ under the ticker symbol "GWPH."

How were GW Pharmaceuticals' earnings last quarter?

GW Pharmaceuticals (NASDAQ:GWPH) announced its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($3.12) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($2.22) by $0.90. The biopharmaceutical company had revenue of $3.35 million for the quarter, compared to analyst estimates of $2.04 million. GW Pharmaceuticals had a negative return on equity of 53.37% and a negative net margin of 1,516.94%. GW Pharmaceuticals's revenue for the quarter was up 112.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.70) earnings per share. View GW Pharmaceuticals' Earnings History.

When is GW Pharmaceuticals' next earnings date?

GW Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for GW Pharmaceuticals.

What price target have analysts set for GWPH?

7 Wall Street analysts have issued 12 month price targets for GW Pharmaceuticals' shares. Their forecasts range from $61.00 to $205.00. On average, they expect GW Pharmaceuticals' share price to reach $152.1429 in the next year. View Analyst Ratings for GW Pharmaceuticals.

What are Wall Street analysts saying about GW Pharmaceuticals stock?

Here are some recent quotes from research analysts about GW Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. " (5/11/2018)
  • 2. Cantor Fitzgerald analysts commented, "Europe Follows Suit. Following acceptance of the Epidiolex application by the FDA in December, GW announced European acceptance of the application today. In the U.S., the review is expedited, with an advisory panel in 2Q18 and a PDUFA date on June, 27 2018. The company expects a European decision by 1Q19." (2/5/2018)

Who are some of GW Pharmaceuticals' key competitors?

Who are GW Pharmaceuticals' key executives?

GW Pharmaceuticals' management team includes the folowing people:
  • Dr. Geoffrey W. Guy BSc, LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCP, Founder & Exec. Chairman (Age 64)
  • Mr. Justin D. Gover, CEO & Exec. Director (Age 47)
  • Mr. Scott M. Giacobello, Chief Financial Officer (Age 48)
  • Mr. Christopher John Tovey BSc, Chief Operating Officer (Age 53)
  • Mr. Douglas B. Snyder, Chief Legal Officer (Age 54)

Has GW Pharmaceuticals been receiving favorable news coverage?

Press coverage about GWPH stock has been trending somewhat positive on Monday, Accern Sentiment reports. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. GW Pharmaceuticals earned a coverage optimism score of 0.11 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.00 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are GW Pharmaceuticals' major shareholders?

GW Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Scopia Capital Management LP (9.78%), BlackRock Inc. (2.79%), Point72 Asset Management L.P. (1.31%), Rock Springs Capital Management LP (1.30%), Victory Capital Management Inc. (1.08%) and Millennium Management LLC (0.86%). View Institutional Ownership Trends for GW Pharmaceuticals.

Which major investors are selling GW Pharmaceuticals stock?

GWPH stock was sold by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, OppenheimerFunds Inc., Franklin Resources Inc., Point72 Asset Management L.P., Hsbc Holdings PLC, AGF Investments Inc., C WorldWide Group Holding A S and Greenleaf Trust. View Insider Buying and Selling for GW Pharmaceuticals.

Which major investors are buying GW Pharmaceuticals stock?

GWPH stock was purchased by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, Millennium Management LLC, Victory Capital Management Inc., UBS Group AG, JPMorgan Chase & Co., Rock Springs Capital Management LP, Alps Advisors Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for GW Pharmaceuticals.

How do I buy shares of GW Pharmaceuticals?

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GW Pharmaceuticals' stock price today?

One share of GWPH stock can currently be purchased for approximately $161.10.

How big of a company is GW Pharmaceuticals?

GW Pharmaceuticals has a market capitalization of $4.47 billion and generates $11 million in revenue each year. The biopharmaceutical company earns $-166,900,000.00 in net income (profit) each year or ($6.95) on an earnings per share basis. GW Pharmaceuticals employs 583 workers across the globe.

How can I contact GW Pharmaceuticals?

GW Pharmaceuticals' mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]


MarketBeat Community Rating for GW Pharmaceuticals (GWPH)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  415 (Vote Outperform)
Underperform Votes:  193 (Vote Underperform)
Total Votes:  608
MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals and other stocks. Vote "Outperform" if you believe GWPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GWPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GW Pharmaceuticals (NASDAQ:GWPH) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for GW Pharmaceuticals in the last 12 months. Their average twelve-month price target is $152.1429, suggesting that the stock has a possible downside of 5.56%. The high price target for GWPH is $205.00 and the low price target for GWPH is $61.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.862.862.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $152.1429$152.1429$150.2857$146.25
Price Target Upside: 5.56% downside14.06% upside13.57% upside27.43% upside

GW Pharmaceuticals (NASDAQ:GWPH) Consensus Price Target History

Price Target History for GW Pharmaceuticals (NASDAQ:GWPH)

GW Pharmaceuticals (NASDAQ:GWPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018CowenReiterated RatingBuy$165.00LowView Rating Details
4/19/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$192.00 ➝ $205.00HighView Rating Details
2/6/2018Bank of AmericaLower Price TargetBuy ➝ Buy$154.00 ➝ $149.00HighView Rating Details
2/6/2018Leerink SwannBoost Price TargetOutperform ➝ Outperform$153.00 ➝ $157.00HighView Rating Details
12/14/2017Goldman Sachs GroupUpgradeNeutral ➝ Buy$174.00MediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$154.00MediumView Rating Details
8/8/2017Maxim GroupDowngradeBuy ➝ Hold$61.00HighView Rating Details
2/7/2017Piper Jaffray CompaniesSet Price TargetBuy$147.00N/AView Rating Details
9/25/2016Morgan StanleyBoost Price TargetOverweight$152.00 ➝ $160.00N/AView Rating Details
8/26/2016Numis SecuritiesUpgradeSell ➝ HoldN/AView Rating Details
6/27/2016Janney Montgomery ScottInitiated CoverageSell$40.00N/AView Rating Details
(Data available from 5/28/2016 forward)

Earnings

GW Pharmaceuticals (NASDAQ:GWPH) Earnings History and Estimates Chart

Earnings by Quarter for GW Pharmaceuticals (NASDAQ:GWPH)

GW Pharmaceuticals (NASDAQ:GWPH) Earnings Estimates

2018 EPS Consensus Estimate: ($3.67)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($2.34)($2.34)($2.34)
Q2 20181$2.50$2.50$2.50
Q3 20181($2.00)($2.00)($2.00)
Q4 20181($1.83)($1.83)($1.83)

GW Pharmaceuticals (NASDAQ GWPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018        
5/8/20183/31/2018($2.22)($3.12)$2.04 million$3.35 millionViewN/AView Earnings Details
2/5/2018Q1 2018($2.03)($2.43)$2.18 million$7.73 millionViewN/AView Earnings Details
12/4/2017Q4 2017($1.73)($2.18)$2.50 million$2.86 millionViewN/AView Earnings Details
8/7/20176/30/2017($1.73)($2.07)$2.10 million$3.14 millionViewListenView Earnings Details
5/9/20173/31/2017($1.50)($1.70)$2.07 million$2.04 millionViewListenView Earnings Details
2/7/2017Q117($1.35)($0.77)$1.85 million$2.54 millionViewListenView Earnings Details
12/5/2016Q416($1.48)($0.89)$2.85 million$2.16 millionViewListenView Earnings Details
8/9/2016Q3 2016($1.73)($0.73)$3.36 million$3.10 millionViewN/AView Earnings Details
5/5/2016Q2 2016($1.71)($1.10)$6.86 million$3.81 millionViewN/AView Earnings Details
2/10/2016Q116($1.53)($0.10)$4.61 million$5.40 millionViewListenView Earnings Details
12/7/2015Q415($1.38)($0.85)$15.00 million$5.60 millionViewN/AView Earnings Details
8/6/2015Q315($1.30)($1.60)$12.82 million$13.55 millionViewN/AView Earnings Details
5/11/2015Q215($1.23)($0.58)$11.38 million$9.43 millionViewListenView Earnings Details
2/4/2015Q115($0.91)($0.26)$12.12 million$12.40 millionViewN/AView Earnings Details
12/2/2014Q414($0.46)$0.02$9.15 million$12.03 millionViewN/AView Earnings Details
8/6/2014Q314($0.62)($0.66)$12.88 million$13.00 millionViewN/AView Earnings Details
5/7/2014Q114($0.30)$0.49$12.48 million$12.55 millionViewN/AView Earnings Details
2/4/2014Q413($0.34)($0.02)$11.54 million$7.49 millionViewN/AView Earnings Details
11/19/2013Q4($0.19)($0.29)$11.42 million$11.52 millionViewListenView Earnings Details
8/5/2013Q313($0.11)$0.02$10.71 million$11.04 millionViewN/AView Earnings Details
6/3/2013Q2 2013($0.26)$11.76 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

GW Pharmaceuticals (NASDAQ:GWPH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

GW Pharmaceuticals (NASDAQ GWPH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 71.69%
Insider Trading History for GW Pharmaceuticals (NASDAQ:GWPH)
Institutional Ownership by Quarter for GW Pharmaceuticals (NASDAQ:GWPH)

GW Pharmaceuticals (NASDAQ GWPH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

GW Pharmaceuticals (NASDAQ GWPH) News Headlines

Source:
DateHeadline
Rescheduling Marijuana in the U.S. Could BackfireRescheduling Marijuana in the U.S. Could Backfire
finance.yahoo.com - May 27 at 8:45 AM
GW Pharmaceuticals (GWPH) Receives Consensus Rating of "Buy" from BrokeragesGW Pharmaceuticals (GWPH) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 25 at 1:04 AM
Cantor Fitzgerald Weighs in on GW Pharmaceuticals FY2018 Earnings (GWPH)Cantor Fitzgerald Weighs in on GW Pharmaceuticals' FY2018 Earnings (GWPH)
www.americanbankingnews.com - May 24 at 8:36 AM
Todays Research Reports on Trending Tickers: GW Pharmaceuticals and Taro PharmaceuticalToday's Research Reports on Trending Tickers: GW Pharmaceuticals and Taro Pharmaceutical
finance.yahoo.com - May 24 at 8:28 AM
How to Invest in MarijuanaHow to Invest in Marijuana
www.fool.com - May 23 at 8:26 AM
GW Pharmaceuticals Reaches Analyst Target PriceGW Pharmaceuticals Reaches Analyst Target Price
www.nasdaq.com - May 23 at 8:26 AM
This Latest Marijuana Survey Should Be Great News for Cannabis-Focused BiotechsThis Latest Marijuana Survey Should Be Great News for Cannabis-Focused Biotechs
finance.yahoo.com - May 23 at 8:26 AM
Bristol-Myers Squibb and Three Additional Stocks Under Scanner in the Drug Makers SpaceBristol-Myers Squibb and Three Additional Stocks Under Scanner in the Drug Makers Space
finance.yahoo.com - May 21 at 8:25 AM
Are Oregon's Marijuana Woes a Precursor of What's to Come in Canada?Are Oregon's Marijuana Woes a Precursor of What's to Come in Canada?
finance.yahoo.com - May 20 at 8:30 AM
GW Pharmaceuticals and US Subsidiary Greenwich Biosciences Announce Publication in The New England Journal of ...GW Pharmaceuticals and US Subsidiary Greenwich Biosciences Announce Publication in The New England Journal of ...
globenewswire.com - May 18 at 8:53 AM
GW Pharma (GWPH) Announces Publication in NEJM of Phase 3 Study of Epidiolex in Lennox-Gastaut SyndromGW Pharma (GWPH) Announces Publication in NEJM of Phase 3 Study of Epidiolex in Lennox-Gastaut Syndrom
www.streetinsider.com - May 17 at 6:10 PM
Cannabis Investors Buzzing Over Canadas Green Organic Dutchman IPOCannabis Investors Buzzing Over Canada's Green Organic Dutchman IPO
finance.yahoo.com - May 17 at 6:10 PM
This Marijuana Stocks Bulls Need a Reality CheckThis Marijuana Stock's Bulls Need a Reality Check
www.msn.com - May 17 at 8:33 AM
5 Things Youll Want to Know About What Could Be the Biggest Medical Marijuana Drug Ever5 Things You'll Want to Know About What Could Be the Biggest Medical Marijuana Drug Ever
www.msn.com - May 17 at 8:33 AM
5 Things You'll Want to Know About What Could Be the Biggest Medical Marijuana Drug Ever5 Things You'll Want to Know About What Could Be the Biggest Medical Marijuana Drug Ever
finance.yahoo.com - May 17 at 8:33 AM
This Marijuana Stock's Bulls Need a Reality CheckThis Marijuana Stock's Bulls Need a Reality Check
finance.yahoo.com - May 17 at 8:33 AM
Market Morning Roundup: Amazon Fumes, Medical Cannabis to Follow Sports Betting?Market Morning Roundup: Amazon Fumes, Medical Cannabis to Follow Sports Betting?
finance.yahoo.com - May 16 at 5:30 PM
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences Announce Publication in The New England Journal of Medicine of a Phase 3 Study of Cannabidiol Oral Solution in Lennox-Gastaut SyndromeGW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences Announce Publication in The New England Journal of Medicine of a Phase 3 Study of Cannabidiol Oral Solution in Lennox-Gastaut Syndrome
finance.yahoo.com - May 16 at 5:30 PM
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences Announce Publication in The New England Journal of Medicine of a Phase 3 Study of Epidiolex® (cannabidiol oral solution) in Lennox-Gastaut SyndromeGW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences Announce Publication in The New England Journal of Medicine of a Phase 3 Study of Epidiolex® (cannabidiol oral solution) in Lennox-Gastaut Syndrome
finance.yahoo.com - May 16 at 5:30 PM
GW Pharmaceuticals (GWPH) Cut to "Hold" at Zacks Investment ResearchGW Pharmaceuticals (GWPH) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 12 at 12:34 AM
BRIEF-GW Pharmaceuticals Qtrly Loss Per ADS 312.0 CentsBRIEF-GW Pharmaceuticals Qtrly Loss Per ADS 312.0 Cents
www.reuters.com - May 10 at 5:45 PM
Cowen Reiterates "Buy" Rating for GW Pharmaceuticals (GWPH)Cowen Reiterates "Buy" Rating for GW Pharmaceuticals (GWPH)
www.americanbankingnews.com - May 9 at 9:42 PM
GW Pharmaceuticals (GWPH) Rating Increased to Buy at BidaskClubGW Pharmaceuticals (GWPH) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - May 9 at 6:39 PM
GW Pharmaceuticals (GWPH) CEO Justin Gover on Q2 2018 Results - Earnings Call TranscriptGW Pharmaceuticals' (GWPH) CEO Justin Gover on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 8:29 AM
GW Pharmaceuticals (GWPH) Stock Moving Higher After Posting Q2 EarningsGW Pharmaceuticals (GWPH) Stock Moving Higher After Posting Q2 Earnings
finance.yahoo.com - May 9 at 8:29 AM
The Only 2 Numbers in This Top Marijuana Stocks Q2 Results That MatterThe Only 2 Numbers in This Top Marijuana Stock's Q2 Results That Matter
www.fool.com - May 9 at 8:29 AM
The Only 2 Numbers in This Top Marijuana Stock's Q2 Results That MatterThe Only 2 Numbers in This Top Marijuana Stock's Q2 Results That Matter
finance.yahoo.com - May 9 at 8:29 AM
GW Pharmaceuticals (GWPH) Announces Quarterly  Earnings ResultsGW Pharmaceuticals (GWPH) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 8 at 10:44 PM
GW Pharmaceuticals misses by $0.64, beats on revenueGW Pharmaceuticals misses by $0.64, beats on revenue
seekingalpha.com - May 8 at 5:29 PM
Interesting GWPH Put And Call Options For January 2020Interesting GWPH Put And Call Options For January 2020
www.nasdaq.com - May 8 at 5:29 PM
Why Marijuana Stock GW Pharmaceuticals Gained 18% in AprilWhy Marijuana Stock GW Pharmaceuticals Gained 18% in April
www.fool.com - May 8 at 2:40 PM
GW Pharmaceuticals (GWPH) Scheduled to Post Earnings on TuesdayGW Pharmaceuticals (GWPH) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - May 7 at 8:46 AM
Better Marijuana Stock: Canopy Growth vs. GW PharmaceuticalsBetter Marijuana Stock: Canopy Growth vs. GW Pharmaceuticals
finance.yahoo.com - May 6 at 7:32 PM
ValuEngine Downgrades GW Pharmaceuticals (GWPH) to HoldValuEngine Downgrades GW Pharmaceuticals (GWPH) to Hold
www.americanbankingnews.com - May 3 at 5:12 PM
GW Pharmaceuticals to Report Second Quarter Financial Results and Host Conference Call on 8 May, 2018GW Pharmaceuticals to Report Second Quarter Financial Results and Host Conference Call on 8 May, 2018
finance.yahoo.com - May 3 at 8:26 AM
GW Pharmaceuticals (GWPH) Given Consensus Rating of "Buy" by AnalystsGW Pharmaceuticals (GWPH) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 30 at 1:32 AM
You'll Never Guess What Jeff Sessions Just Said About MarijuanaYou'll Never Guess What Jeff Sessions Just Said About Marijuana
finance.yahoo.com - April 29 at 6:32 PM
Cannabis Industry Sits on Precipice of Major ExpansionCannabis Industry Sits on Precipice of Major Expansion
finance.yahoo.com - April 28 at 8:42 AM
Opinion: What to expect from marijuana stocks after the first big medical cannabis winOpinion: What to expect from marijuana stocks after the first big medical cannabis win
www.marketwatch.com - April 26 at 8:24 AM
Epilepsy Drug Fuels Cannabis-Stock BuzzEpilepsy Drug Fuels Cannabis-Stock Buzz
www.barrons.com - April 25 at 5:23 PM
GW Pharmaceuticals (GWPH) Upgraded at Zacks Investment ResearchGW Pharmaceuticals (GWPH) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 24 at 11:34 AM
What Lies Ahead for Vice ETFs?What Lies Ahead for Vice ETFs?
finance.yahoo.com - April 24 at 8:26 AM
The Simple Reason Why Marijuana Stock Valuations Aren't as Sky-High as They SeemThe Simple Reason Why Marijuana Stock Valuations Aren't as Sky-High as They Seem
finance.yahoo.com - April 22 at 8:26 AM
FDA Committee Approval Sparks Bullishness On GW PharmaFDA Committee Approval Sparks Bullishness On GW Pharma
seekingalpha.com - April 20 at 5:14 PM
FDA Panel Backs Proposed Epilepsy Drug Derived From CannabisFDA Panel Backs Proposed Epilepsy Drug Derived From Cannabis
www.wsj.com - April 20 at 5:14 PM
An Incredible Signal: 4 Experts Weigh In On Positive FDA Panel Vote For GW Pharmas Epidiolex'An Incredible Signal': 4 Experts Weigh In On Positive FDA Panel Vote For GW Pharma's Epidiolex
www.msn.com - April 20 at 8:36 AM
20 Marijuana Facts for 4/2020 Marijuana Facts for 4/20
finance.yahoo.com - April 20 at 8:36 AM
FDA Close to Approving First Cannabis-Based DrugFDA Close to Approving First Cannabis-Based Drug
finance.yahoo.com - April 20 at 8:36 AM
GW Pharma wins unanimous recommendation from FDA advisory committee for cannabis-derived drugGW Pharma wins unanimous recommendation from FDA advisory committee for cannabis-derived drug
www.marketwatch.com - April 19 at 5:31 PM
Why This Kids Epilepsy Drug Is Almost Certainly About to Become the 1st FDA Approved Marijuana TreatmentWhy This Kids' Epilepsy Drug Is Almost Certainly About to Become the 1st FDA Approved Marijuana Treatment
fortune.com - April 19 at 5:31 PM

SEC Filings

GW Pharmaceuticals (NASDAQ:GWPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

GW Pharmaceuticals (NASDAQ:GWPH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

GW Pharmaceuticals (NASDAQ GWPH) Stock Chart for Monday, May, 28, 2018

Loading chart…

This page was last updated on 5/28/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.